| Name | Title | Contact Details |
|---|
Greffexâ„¢ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAXâ„¢ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex`s team designs and produces a GREVAXâ„¢ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAXâ„¢ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.
Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cantimer is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cell Biosciences Inc is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.